Drug Development

In a trial led by Stanford Medicine researchers, more than half of patients with persistent smell loss saw improvement with injections of platelet-rich plasma.

The collaboration will enable the development of medications to treat a type of brain cancer.

A discovery by Stanford Medicine researchers and colleagues may pave the way for a “morning after” or prophylactic nasal spray to prevent infection.

In a new clinical trial, Stanford Medicine researchers found that a commonly used anti-nausea drug could reduce the severity of opioid withdrawal in newborns.

Robert Malenka’s early research on the molecular mechanisms underlying memory and learning has led to an understanding of their role in psychiatric disorders including addiction, depression and autism spectrum disorder.

Stanford Medicine researchers have created a molecule that blocks an enzyme thought to be instrumental in causing colon cancer relapse or chemotherapy resistance.

Levels of a stringy, spongy substance soar in the sputum of COVID-19 patients requiring intubation, accounting for at least some of their breathing trouble. Development of an off-patent drug may prevent it.

Stanford Medicine now provides a test for the mpox virus. Rapid identification of infected people will help combat the virus’s spread and facilitate patient care.

Stanford Medicine’s SyneRx will develop drugs to fight viral pathogens with high pandemic potential, including the one that causes COVID-19.

Using household items, Stanford students have developed a way to make affordable nasal drops with the potential to slow the spread of viruses like COVID-19.

Stanford researchers have been working on gene therapies for epidermolysis bullosa, or “butterfly disease,” for over a decade. A new gel helped wounds heal and stay healed in a clinical trial.